Isolation of 6-Gingerol from the Rhizome of Zinger (Zingiber officinale) and Evaluation of its Effect on the Bone Health of Streptozotocin-Induced Diabetic Rats
Article Sidebar
Main Article Content
Abstract
Several studies have investigated the effects of various natural products on bone mineral density, bone mineral content, and fat content. The present study aims to isolate, characterize 6-gingerol and investigate its effect in diabetic osteoporosis. Isolation and identification of 6-gingerol was done by a combination of column chromatography (CC), thin-layer chromatography (TLC) and high performance liquid chromatography (HPLC). The effects of 6-gingerol on diabetic osteoporosis was assessed for 17 weeks (120 days) in streptozotocin (STZ)-induced diabetic rats. The animals were divided into four groups: Group 1 (control rats), Group 2 (diabetic rats), Group 3 (diabetic rats treated with 6-gingerol at 100 mg/kg body weight), and Group 4 (control rats treated with 6-gingerol). Bone mineral density, bone mineral content, fat mass, and total lean mass in all the experimental rats were evaluated at the end of the study using dual-energy X-ray absorptiometry (DEXA). The diabetic rats treated with 6-gingerol showed improved blood glucose level compared to the untreated diabetic rats. Diabetic rats showed fluctuating values of total fat, percentage fat, bone mineral density (BMD), and bone mineral content (BMC). However, following 120 days of treatment with 6-gingerol, all variables were similar to that obtained in the control group. The findings from the present study reveal that 6-gingerol has the propensity to prevent glucotoxicity-induced diabetic osteoporosis while improving bone health.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Risnick HE, Bauer DC, Tylavsky FA, Nathalie de Rekeneire, Harris TB, Newman AB. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005; 165(14):1612–1617.
Schwartz AV, Sellmeyer DE, Ensrud KE, CauleyJA, Tabor HK, Schreiner PJ. Older women withdiabetes have an increased risk of fracture: a prospective study. J ClinEndocrinolMetab. 2001; 86(1):32–38.
Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5) :495–505.
Melton LJ, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a populationbased study. J Bone Miner Res. 2008; 23:1334–1342.
Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodrigueze BL, Jhonson KC, Margolis KL. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J ClinEndocrinolMetab. 2006; 91(9):3404–3410.
Doyle F, Brown J, Lachance C. Relation between bone mass and muscle weight. Lancet. 1970; 1:391–393.
Fang ZB, Wang GX, Cai GZ, Zhang PX, Liu DL, Chu SF, Li HL, Zhao HX. Association between fatty acids intake and bone mineral density in adults aged 20-50: NHANES 2011-2018. Front Nutr. 2023; 10:1-9.
Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent- Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, Meunier PJ. How hip and whole-body bone mineral density predict hip fracture in elderly women: The EPIDOS prospective study. Osteoporos Int. 1998; 8:247–254.
Lau EMC, Chan YH, Chan M, Woo J, Griffith J, Chan HHL, Leung PC. Vertebral deformity in Chinese men: Prevalence, risk factors, bone mineral density, and body composition measurements. Calcif Tissue Int. 2008; 66:47–52.
Wiklund P, Toss F, Jansson JH, Eliasson M, Hallmans G, Nordstrom A, Franks PW, Nordstrom P. Abdominal and gynoid adipose distribution and incident myocardial infarction in women and men. Int J Obes (Lond). 2010; 34(12):1752-1758.
Despres JP. Cardiovascular disease under the influence of excess visceral fat. CritPathwCardiol. 2007; 6:51–59.
Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trondelag Health Survey. Diabetol. 1999; 42:920–925.
Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol. 1993; 137:1203–1211.
Nicodemus KK and Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001; 24:1192–1197.
Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Black DM, Cummings SR. Older women with diabetes have an increased risk of fracture: A prospective study. J ClinEndocrinolMetab. 2001; 86:32–38.
Simoneau GG, Ulbrecht JS, Derr JA, Becker MB, Cavanagh PR. Postural instability in patients with diabetic sensory neuropathy. Diabetes Care. 1994; 17:1411–1421.
Almatroodi SA, Alnuqaydan AM, Babiker AY, Almogbel MA, Khan AA, Husain Rahmani A. 6-Gingerol, a Bioactive Compound of Ginger Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats by Regulating the Oxidative Stress and Inflammation. Pharmaceutics. 2021; 13(3):317.
Alharbi KS, Nadeem MS, Afzal O, Alzarea SI, Altamimi ASA, Almalki WH, Mubeen B, Iftikhar S, Shah L, Kazmi I. Gingerol, a Natural Antioxidant, Attenuates Hyperglycemia and Downstream Complications. Metabolites 2022; 12(12):1274.
Fuhrman B, Rosenblat M, Hayek T, Coleman R, Aviram M. Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. J Nutr. 2000; 130: 1124–1131.
Suzer B, Seyidoglu N, Tufekci K, Karakci D, Bakır B. A Preventive herb against bone loss in diabetic rats: Zingiber officinale. J Istanbul Vet Sci. 2022; 6(2):76-83.
Sheikhhossein F, Borazjani M, Jafari A, Askari M, Vataniyan E, Gholami F, Reza Amini Md. Effects of ginger supplementation on biomarkers of oxidative stress: A systematic review and meta-analysis of randomized controlled trials. ClinNutr. 2021; 45:111–119.
Ajayi BO, Adedara IA, Farombi EO. 6-Gingerol abates benzo[a]pyrene-induced colonic injury via suppression of oxido-inflammatory stress responses in BALB/c mice. ChemBiol Interact. 2019; 307:1–7.
Nammi S, Sreemantula S, Roufogalis BD. Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. Basic ClinPharmacolToxicol. 2009; 104:366–373.
Siregar RS, Hadiguna RA, KamilI,Nazir N, Nofialdi N. Ginger (Zingiber officinale R.) as a Potent Medicinal Plant for the Prevention and Treatment of Diabetes Mellitus: A Review. Trop J Nat Prod Res. 2022; 6(4):462-469.
Puengphian C and Sirichote A. [6]-gingerol content and bioactive properties of ginger (Zingiber officinale Roscoe) extracts from supercritical CO2 extraction. Asian J Food Agric Ind. 2008; 1(01):29-36.
Maghraby YR, Labib RM, Sobeih M, Farag MA. Gingerols and shogaols: A multi-faceted review of their extraction, formulation, and analysis in drugs and biofluids to maximize their nutraceutical and pharmaceutical applications. Food Chem: X. 2023:100947.
Chakraborty D, Mukherjee A, Sikdar S, Paul A, Gosh S, Rahman A et al. [6]- Gingerol isolated from ginger attenuates sodium arsenite induced oxidative stress and plays a corrective role in improving insulin signaling in mice. Toxicology Letters, 2012; 210(1):34-43.
Lee SH, Cekanova M, Baek SJ. Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Molecular Carcinogen. 2008; 47(3):197-208.
Kuhad A, Tirkey N, Pilkhwal S, Chopra K. 6-Gingerol prevents cisplatin induced acute renal failure in rats. Bio Factors. 2006; 26(3):189-200.
Jafri SA, Abass S, Qasim M. Hypoglycemic effect of ginger (Zingiber officinale) in alloxan induced diabetic rats (Rattus norvagicus). Pak Vet J. 2011; 31(2):160-162.
Schwartz AV. Clinical aspects of diabetic bone disease: An update. Clin Rev Bone Min Metab. 2013; 11: 17–27.
Dhaon P and Shah VN. Type 1 diabetes and osteoporosis: A review of literature. Indian J Endocrinol. Metab. 2014;18:159–165.
Hamann C, Kirschner S, KlausPeter G. Bone, sweet bone osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012; 8:297–309.
Piscitelli P, Neglia C, Vigilanza A, Colao A. Diabetes and bone: Biological and environmental factors. CurrOpinEndocrinol Diabetes Obes. 2015; 22: 439–445.
Roy B. Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures. World J. Diabetes. 2013; 4:101–113.
Li Y, Tran VH, Duke CC, Basil D, Roufogalis. Preventive and Protective Properties of Zingiber officinale (Ginger) in DiabetesMellitus, Diabetic Complications, and Associated Lipid and Other Metabolic Disorders: A Brief Review.Hindawi-Evi-Based Complement Altern Med. 2012; Article ID 516870: 10 pages.
Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP. Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study. J Bone Miner Res. 2000; 15:710–720.
Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan GA, Salonen JT. Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care. 1998; 21:1637–1643.
Looker HC, Knowler WC, Hanson RL. Changes in BMI and weight before and after the development of type 2 diabetes. Diabetes Care. 2000; 24:1917–1922.
Wu F, Ames R, Clearwater J, Evans MC, Gamble G, Reid IR. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. ClinEndocrinol (Oxf). 2002; 56(6):703–711.
Samad MB, Mohsin MNAB, Razu BA, Hossain MT, Mahzabeen S, Unnoor N, Muna IA, Akhter F, Kabir AU, Hannan JMA. [6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Leprdb/db type 2 diabetic mice. BMC Complement Altern Med. 2017; 17:395.
Greco EA, Fornari R, Rossi F, Santiemma V, Prossomariti G, Annoscia C, A Aversa, M Brama, M Marini, L M Donini, GSpera, A Lenzi, C Lubrano, S Migliaccio. Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J ClinPract. 2010; 64:817–820.
Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012; 27(11): 2231–7.
De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int. 2005; 16:1330–1338.
Manolagas SC. From estrogen centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010; 31(3):266–300.
Sroga GE and Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. CurrOsteoporos Rep. 2012; 10(2):141–150.
Okamoto M, Irii H, Tahara Y, Ishii H, Hirao A, Udagawa H, Hiramoto M, Yasuda K, Takanishi A, Shibata S, Shimizu I. Synthesis of a New [6]-Gingerol Analogue and Its Protective Effect with Respect to the Development of Metabolic Syndrome in Mice Fed a High-Fat Diet. J Med Chem. 2011; 54: 6295–6304.